ATE538099T1 - 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden - Google Patents

2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden

Info

Publication number: ATE538099T1
Authority: AT; Austria
Prior art keywords: phenyl; hydroxy; methyl; derivatives; glucocorticoid receptor
Prior art date: 2006-10-23

Application number

AT07867264T

Other languages

English (en)

Inventor

Christopher J Bungard

Jesse J Manikowski

James J Perkins

Robert Meissner

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-23

Filing date

2007-10-23

Publication date

2012-01-15

2007-10-23 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538099T1 publication Critical patent/ATE538099T1/de

Links

102000003676 Glucocorticoid Receptors Human genes 0.000 title abstract 2
108090000079 Glucocorticoid Receptors Proteins 0.000 title abstract 2
239000003446 ligand Substances 0.000 title abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
230000001363 autoimmune Effects 0.000 abstract 1
125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Virology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)

AT07867264T 2006-10-23 2007-10-23 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden ATE538099T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US85365506P	2006-10-23	2006-10-23
US92333707P	2007-04-13	2007-04-13
PCT/US2007/022449 WO2008060391A2 (en)	2006-10-23	2007-10-23	2- [l-phenyl-5-hydr0xy-4alpha-methyl-hexahydr0cycl0penta[f] indaz0l-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands

Publications (1)

Publication Number	Publication Date
ATE538099T1 true ATE538099T1 (de)	2012-01-15

Family

ID=39030900

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07867264T ATE538099T1 (de)	2006-10-23	2007-10-23	2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden

Country Status (19)

Country	Link
US (1)	US8119681B2 (de)
EP (2)	EP2097385B1 (de)
JP (1)	JP5271911B2 (de)
KR (1)	KR20090068345A (de)
CN (1)	CN101528707B (de)
AT (1)	ATE538099T1 (de)
AU (1)	AU2007309507A1 (de)
BR (1)	BRPI0718505A2 (de)
CA (1)	CA2667007A1 (de)
CO (1)	CO6190517A2 (de)
CR (1)	CR10771A (de)
EA (1)	EA200970401A1 (de)
IL (1)	IL198226A0 (de)
MA (1)	MA30870B1 (de)
MX (1)	MX2009004385A (de)
NO (1)	NO20092004L (de)
SV (1)	SV2009003233A (de)
TN (1)	TN2009000149A1 (de)
WO (2)	WO2008060391A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200829578A (en)	2006-11-23	2008-07-16	Astrazeneca Ab	Chemical compounds 537
JO2754B1 (en)	2006-12-21	2014-03-15	استرازينكا ايه بي	Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
EP2532350A1 (de) *	2007-10-17	2012-12-12	Laboratoire HRA Pharma	Pharmazeutische Kombinationen mit einem Glucocorticoid Rezeptorantagonist und einem Cortisol Synthasehemmer zur Behandlung des Cushing-Syndroms
AU2008317484A1 (en) *	2007-10-23	2009-04-30	Merck Sharp & Dohme Corp.	Process for making glucocorticoid receptor ligands
UY31832A (es)	2008-05-20	2010-01-05	Astrazeneca Ab	Derivados de indazol sustituidos con fenilo y benzodioxinilo
WO2010138421A1 (en) *	2009-05-27	2010-12-02	Merck Sharp & Dohme Corp.	HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
WO2010141247A1 (en)	2009-06-02	2010-12-09	Merck Sharp & Dohme Corp.	Hexahydrocyclopentyl[∫]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
WO2011031574A1 (en) *	2009-09-08	2011-03-17	Merck Sharp & Dohme Corp.	HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
EP2493303A4 (de) *	2009-10-30	2013-06-26	Merck Sharp & Dohme	2- [1-phenyl-5-hydroxy-4a-substitutierte-hexahydrocyclopenta [f]indazol-5-yl]ethylphenylderivate als glucocorticoidrezeptorliganden
HK1203412A1 (en)	2011-12-28	2015-10-30	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102142A1 (en)	2011-12-28	2013-07-04	Global Blood Therapeutics, Inc.	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en)	2013-03-15	2015-09-30	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en)	2013-03-15	2018-05-30	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (de)	2013-03-15	2024-08-28	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
ES2860648T5 (es)	2014-02-07	2024-11-27	Global Blood Therapeutics Inc	Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
MA41841A (fr)	2015-03-30	2018-02-06	Global Blood Therapeutics Inc	Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
ES2865334T3 (es)	2015-08-13	2021-10-15	Corcept Therapeutics Inc	Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
US11020382B2 (en)	2015-12-04	2021-06-01	Global Blood Therapeutics, Inc.	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CA3011728A1 (en)	2016-01-19	2017-07-27	Corcept Therapeutics, Inc.	Differential diagnosis of ectopic cushing's syndrome
TWI825524B (zh)	2016-05-12	2023-12-11	美商全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10195214B2 (en)	2017-03-01	2019-02-05	Corcept Therapeutics, Inc.	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
EP3860975B1 (de)	2018-10-01	2023-10-18	Global Blood Therapeutics, Inc.	Modulatoren von hämoglobin zur behandlung von sichelzellenanämie
WO2020234103A1 (en)	2019-05-21	2020-11-26	Bayer Aktiengesellschaft	Identification and use of kras inhibitors
US11285145B2 (en)	2020-05-27	2022-03-29	Corcept Therapeutics Incorporated	Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846839B1 (en) *	1995-06-07	2005-01-25	Sugen, Inc.	Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
CA2473886C (en)	2002-01-22	2012-08-21	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
EP1496892B1 (de) *	2002-04-11	2011-01-26	Merck Sharp & Dohme Corp.	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
EP1599201B1 (de) *	2003-02-25	2010-04-14	Merck Sharp & Dohme Corp.	Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren
ATE447575T1 (de) *	2003-04-23	2009-11-15	Merck & Co Inc	Selektive spirocyclische glucocorticoid-rezeptor- modulatoren

2007
- 2007-10-23 MX MX2009004385A patent/MX2009004385A/es unknown
- 2007-10-23 KR KR1020097008368A patent/KR20090068345A/ko not_active Withdrawn
- 2007-10-23 BR BRPI0718505-7A patent/BRPI0718505A2/pt not_active Application Discontinuation
- 2007-10-23 EP EP07839748A patent/EP2097385B1/de active Active
- 2007-10-23 JP JP2009534622A patent/JP5271911B2/ja not_active Expired - Fee Related
- 2007-10-23 US US12/445,901 patent/US8119681B2/en not_active Expired - Fee Related
- 2007-10-23 CN CN2007800392434A patent/CN101528707B/zh not_active Expired - Fee Related
- 2007-10-23 AT AT07867264T patent/ATE538099T1/de active
- 2007-10-23 CA CA002667007A patent/CA2667007A1/en not_active Abandoned
- 2007-10-23 WO PCT/US2007/022449 patent/WO2008060391A2/en not_active Ceased
- 2007-10-23 AU AU2007309507A patent/AU2007309507A1/en not_active Abandoned
- 2007-10-23 WO PCT/US2007/022463 patent/WO2008051532A1/en not_active Ceased
- 2007-10-23 EA EA200970401A patent/EA200970401A1/ru unknown
- 2007-10-23 EP EP07867264A patent/EP2091922B1/de not_active Withdrawn - After Issue
2009
- 2009-04-19 IL IL198226A patent/IL198226A0/en unknown
- 2009-04-21 SV SV2009003233A patent/SV2009003233A/es not_active Application Discontinuation
- 2009-04-21 TN TNP2009000149A patent/TN2009000149A1/fr unknown
- 2009-04-22 CO CO09040679A patent/CO6190517A2/es not_active Application Discontinuation
- 2009-05-06 CR CR10771A patent/CR10771A/es not_active Application Discontinuation
- 2009-05-07 MA MA31847A patent/MA30870B1/fr unknown
- 2009-05-22 NO NO20092004A patent/NO20092004L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA200970401A1 (ru)	2009-10-30
NO20092004L (no)	2009-07-22
BRPI0718505A2 (pt)	2013-11-12
JP2010507663A (ja)	2010-03-11
US20100311709A1 (en)	2010-12-09
EP2091922A2 (de)	2009-08-26
IL198226A0 (en)	2009-12-24
WO2008051532A1 (en)	2008-05-02
JP5271911B2 (ja)	2013-08-21
CN101528707A (zh)	2009-09-09
CO6190517A2 (es)	2010-08-19
CR10771A (es)	2009-05-25
MA30870B1 (fr)	2009-11-02
EP2097385A1 (de)	2009-09-09
WO2008060391A3 (en)	2008-09-25
CN101528707B (zh)	2012-11-07
EP2091922B1 (de)	2011-12-21
TN2009000149A1 (en)	2010-10-18
EP2097385B1 (de)	2012-08-01
CA2667007A1 (en)	2008-05-02
US8119681B2 (en)	2012-02-21
SV2009003233A (es)	2009-10-19
MX2009004385A (es)	2009-05-22
AU2007309507A1 (en)	2008-05-02
WO2008060391A2 (en)	2008-05-22
KR20090068345A (ko)	2009-06-26

Publication	Publication Date	Title
ATE538099T1 (de)	2012-01-15	2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
EA201001682A1 (ru)	2011-06-30	Производные фенил- и бензодиоксинилзамещенных индазолов
ATE549336T1 (de)	2012-03-15	Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
ATE542799T1 (de)	2012-02-15	Chinolinonderivate als parp und tank-inhibitoren
ATE541572T1 (de)	2012-02-15	Tetrahydro-naphtalinderviate als glucocorticoidrezeptor-modulatoren
NO20070489L (no)	2007-03-07	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA200870196A1 (ru)	2009-02-27	Индолсульфонамидные модуляторы рецепторов прогестерона
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20090979L (no)	2009-05-06	(3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
NO20082285L (no)	2008-06-18	3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
ATE500222T1 (de)	2011-03-15	Benzamid- und heteroarenderivate als cetp- inhibitoren
ATE384039T1 (de)	2008-02-15	Indanderivate als muscarinrezeptoragonisten
ATE517873T1 (de)	2011-08-15	6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2009006473A (es)	2009-08-25	Inhibidores de receptor vainilloide de bencimidazol.
NO20085317L (no)	2009-02-05	Imidazoazepinonforbindelser
EA200900090A1 (ru)	2009-06-30	Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
ATE552246T1 (de)	2012-04-15	Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
EP1599201A4 (de)	2007-01-24	Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren
GEP20135804B (en)	2013-04-10	Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester introduced therein as substituent
ATE474574T1 (de)	2010-08-15	Imidazoazephinonverbindungen
EA200801145A1 (ru)	2008-10-30	Спироциклические производные хиназолина в качестве ингибиторов pde7
NO20076161L (no)	2007-11-29	Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
ATE546448T1 (de)	2012-03-15	Urotensin-ii-rezeptorantagonisten
BRPI0516602A (pt)	2008-09-16	composto, e, composição farmacêutica
DE602007005387D1 (de)	2010-04-29	Ptors